70.76
Ani Pharmaceuticals Inc stock is traded at $70.76, with a volume of 385.84K.
It is up +0.01% in the last 24 hours and up +4.66% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$70.75
Open:
$70.83
24h Volume:
385.84K
Relative Volume:
1.26
Market Cap:
$1.49B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
86.29
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
+2.63%
1M Performance:
+4.66%
6M Performance:
+19.91%
1Y Performance:
+8.03%
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ANIP
Ani Pharmaceuticals Inc
|
70.76 | 1.49B | 486.82M | 18.78M | 100.45M | 0.82 |
![]()
ZTS
Zoetis Inc
|
155.43 | 66.90B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.28 | 48.25B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.28 | 47.13B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.58 | 16.06B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
300.76 | 13.15B | 2.76B | 1.11B | 898.10M | 22.77 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-14-25 | Initiated | Jefferies | Buy |
Mar-12-25 | Initiated | JP Morgan | Overweight |
Dec-11-24 | Initiated | Leerink Partners | Outperform |
Oct-11-24 | Initiated | Piper Sandler | Overweight |
Mar-15-24 | Initiated | CapitalOne | Overweight |
Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
Mar-01-23 | Initiated | Guggenheim | Buy |
Sep-07-22 | Initiated | H.C. Wainwright | Buy |
Nov-02-21 | Initiated | Truist | Buy |
May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-12-19 | Initiated | Guggenheim | Buy |
May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
Jul-31-17 | Initiated | Canaccord Genuity | Buy |
Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
Jun-23-16 | Initiated | Raymond James | Strong Buy |
May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
Nov-13-15 | Initiated | Standpoint Research | Buy |
Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
Aug-05-15 | Reiterated | Oppenheimer | Outperform |
Aug-04-15 | Reiterated | ROTH Capital | Neutral |
Jul-31-15 | Reiterated | Oppenheimer | Outperform |
Jul-15-15 | Reiterated | ROTH Capital | Neutral |
Jun-23-15 | Reiterated | Oppenheimer | Outperform |
May-18-15 | Reiterated | ROTH Capital | Neutral |
May-06-15 | Reiterated | Oppenheimer | Outperform |
Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
Feb-26-15 | Reiterated | ROTH Capital | Buy |
Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
The 4.0% return this week takes ANI Pharmaceuticals' (NASDAQ:ANIP) shareholders three-year gains to 135% - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Zacks.com featured highlights include Heritage Insurance, Marex, Kingstone, ANI Pharmaceuticals and HCI - TradingView
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Zacks.com featured highlights include ANI Pharmaceuticals, Heritage Insurance, Avista and Exelon - Yahoo Finance
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue - TradingView
Truist raises ANI Pharmaceuticals target to $65, maintains hold - Investing.com India
Truist raises ANI Pharmaceuticals target to $65, maintains hold By Investing.com - Investing.com Canada
Truist Lifts Price Target on ANI Pharmaceuticals to $65 From $62, Keeps Hold Rating - marketscreener.com
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart.com
Ani Pharmaceuticals Sr. VP sells $27,583 in stock By Investing.com - Investing.com Canada
StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell - MarketBeat
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
ANI Pharmaceuticals (ANIP) Set for Potential Earnings Beat - GuruFocus
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewswire
ANI Pharmaceuticals Reveals Q1 2025 Earnings Date: Key Executive Insights Coming May 9 - Stock Titan
Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO - TradingView
ANI Pharmaceuticals at RBC Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada
Is The Options Market Predicting A Spike In ANI Pharmaceuticals (ANIP) Stock? - Barchart.com
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals To Present At RBC Capital Markets Conference; Webcast At 7:45 AM ET - Nasdaq
Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - Yahoo Finance
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - TradingView
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Alimera Sciences announces change to SmPC allowing all United Kingdom (Great Britain and Northern Ireland) qualified ophthalmic healthcare professionals experienced in intravitreal injections to administer ILUVIEN - PharmiWeb.com
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech
ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):